|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
3
|
Parkin DM, Bray F, Ferlay J, et al: Global
cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
4
|
Van Hagen P, Hulshof MC, van Lanschot JJ,
et al: Preoperative chemoradiotherapy for esophageal or junctional
cancer. N Engl J Med. 366:2074–2084. 2012.
|
|
5
|
Ajani JA, Barthel JS, Bentrem DJ, et al:
Esophageal and esophagogastric junction cancers. J Natl Compr Canc
Netw. 9:830–887. 2011.PubMed/NCBI
|
|
6
|
Ajani JA, Correa AM, Hofstetter WL, et al:
Clinical parameters model for predicting pathologic complete
response following preoperative chemoradiation in patients with
esophageal cancer. Ann Oncol. 23:2638–2642. 2012. View Article : Google Scholar
|
|
7
|
Cheedella NK, Suzuki A, Xiao L, et al:
Association between clinical complete response and pathological
complete response after preoperative chemoradiation in patients
with gastroesophageal cancer: analysis in a large cohort. Ann
Oncol. 24:2854–2859. 2012.
|
|
8
|
Welsh J, Settle SH, Amini A, et al:
Failure patterns in patients with esophageal cancer treated with
definitive chemoradiation. Cancer. 118:2632–2640. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sims-Mourtada J, Izzo JG, Apisarnthanarax
S, et al: Hedgehog: an attribute to tumor regrowth after
chemoradiotherapy and a target to improve radiation response. Clin
Cancer Res. 12:6565–6572. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sims-Mourtada J, Izzo JG, Ajani J, et al:
Sonic Hedgehog promotes multiple drug resistance by regulation of
drug transport. Oncogene. 26:5674–5679. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang Y, Ding Q, Yen CJ, et al: The
crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell.
21:374–387. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yen CJ, Izzo JG, Lee DF, et al: Bile acid
exposure up-regulates tuberous sclerosis complex 1/mammalian target
of rapamycin pathway in Barrett’s-associated esophageal
adenocarcinoma. Cancer Res. 68:2632–2640. 2008.PubMed/NCBI
|
|
13
|
Bao B, Wang Z, Ali S, et al: Metformin
inhibits cell proliferation, migration and invasion by attenuating
CSC function mediated by deregulating miRNAs in pancreatic cancer
cells. Cancer Prev Res (Phila). 5:355–364. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hirsch HA, Iliopoulos D, Tsichlis PN, et
al: Metformin selectively targets cancer stem cells, and acts
together with chemotherapy to block tumor growth and prolong
remission. Cancer Res. 69:7507–7511. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hirsch HA, Iliopoulos D and Struhl K:
Metformin inhibits the inflammatory response associated with
cellular transformation and cancer stem cell growth. Proc Natl Acad
Sci USA. 110:972–977. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bednar F and Simeone DM: Metformin and
cancer stem cells: old drug, new targets. Cancer Prev Res (Phila).
5:351–354. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vazquez-Martin A, Oliveras-Ferraros C,
Cufi S, et al: Metformin regulates breast cancer stem cell ontogeny
by transcriptional regulation of the epithelial-mesenchymal
transition (EMT) status. Cell Cycle. 9:3807–3814. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pierotti MA, Berrino F, Gariboldi M, et
al: Targeting metabolism for cancer treatment and prevention:
metformin, an old drug with multi-faceted effects. Oncogene.
32:1475–1487. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gu Y, Lin S, Li JL, et al: Altered
LKB1/CREB-regulated transcription co-activator (CRTC) signaling
axis promotes esophageal cancer cell migration and invasion.
Oncogene. 31:469–479. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Skinner HD, McCurdy MR, Echeverria AE, et
al: Metformin use and improved response to therapy in esophageal
adenocarcinoma. Acta Oncol. 52:1002–1009. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Raju U, Ariga H, Koto M, et al:
Improvement of esophageal adenocarcinoma cell and xenograft
responses to radiation by targeting cyclin-dependent kinases.
Radiother Oncol. 80:185–191. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Soldes OS, Kuick RD, Thompson IA II, et
al: Differential expression of Hsp27 in normal oesophagus,
Barrett’s metaplasia and oesophageal adenocarcinomas. Br J Cancer.
79:595–603. 1999.PubMed/NCBI
|
|
23
|
Zhang P, Yang Y, Nolo R, et al: Regulation
of NOTCH signaling by reciprocal inhibition of HES1 and Deltex 1
and its role in osteosarcoma invasiveness. Oncogene. 29:2916–2926.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Song S, Maru DM, Ajani JA, et al: Loss of
TGF-beta adaptor beta2SP activates notch signaling and SOX9
expression in esophageal adenocarcinoma. Cancer Res. 73:2159–2169.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Song S, Mazurek N, Liu C, et al:
Galectin-3 mediates nuclear beta-catenin accumulation and Wnt
signaling in human colon cancer cells by regulation of glycogen
synthase kinase-3beta activity. Cancer Res. 69:1343–139. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shank JJ, Yang K, Ghannam J, et al:
Metformin targets ovarian cancer stem cells in vitro and
in vivo. Gynecol Oncol. 127:390–397. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vogelstein B, Papadopoulos N, Velculescu
VE, et al: Cancer genome landscapes. Science. 339:1546–1558. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rosen JM and Jordan CT: The increasing
complexity of the cancer stem cell paradigm. Science.
324:1670–1673. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dulak AM, Schumacher SE, van Lieshout J,
et al: Gastrointestinal adenocarcinomas of the esophagus, stomach,
and colon exhibit distinct patterns of genome instability and
oncogenesis. Cancer Res. 72:4383–4393. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dulak AM, Stojanov P, Peng S, et al: Exome
and whole-genome sequencing of esophageal adenocarcinoma identifies
recurrent driver events and mutational complexity. Nat Genet.
45:478–486. 2013. View
Article : Google Scholar
|
|
31
|
Prins MJ, Verhage RJ, Ruurda JP, et al:
Over-expression of phosphorylated mammalian target of rapamycin is
associated with poor survival in oesophageal adenocarcinoma: a
tissue microarray study. J Clin Pathol. 66:224–228. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kobayashi M, Kato K, Iwama H, et al:
Antitumor effect of metformin in esophageal cancer: in vitro study.
Int J Oncol. 42:517–524. 2013.PubMed/NCBI
|
